18 June 2013 - 18 June 2013 - US molecular diagnostics company GenMark Diagnostics Inc (NASDAQ:GNMK) said yesterday it had downgraded its annual revenue forecast to some USD 30 million (EUR 22.4m) from USD 35 million, as previously guided.

The company explained its move with expected uncertainties associated with the future revenue contribution from its largest customer, as well as with reimbursement and other challenges, which affect the pharmacogenomics sector.

For the first three months of the year, GenMark posted a 414% rise in revenue, which stood at USD 11.1 million. During the period under review, the company has managed to narrowed its net loss to USD 4.2 million from USD 5.6 million in January-March 2012.

(USD 1.0 = EUR 0.747)